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Overexpression of α‑synuclein 
in oligodendrocytes does not increase 
susceptibility to focal striatal excitotoxicity
Daniela Kuzdas‑Wood1†, Lisa Fellner1†, Melanie Premstaller1, Carlijn Borm2, Bastiaan Bloem2, Deniz Kirik3, 
Gregor K. Wenning1 and Nadia Stefanova1*
Abstract 
Background: Multiple system atrophy (MSA) is a fatal adult‑onset neurodegenerative disease characterized by 
α‑synuclein (α‑syn) positive oligodendroglial cytoplasmic inclusions. The latter are associated with a neuronal multi‑
system neurodegeneration targeting central autonomic, olivopontocerebellar and striatonigral pathways, however 
the underlying mechanisms of neuronal cell death are poorly understood. Previous experiments have shown that 
oligodendroglial α‑syn pathology increases the susceptibility to mitochondrial stress and proteasomal dysfunction 
leading to enhanced MSA‑like neurodegeneration. Here we analyzed whether oligodendroglial α‑syn overexpression 
in a transgenic mouse model of MSA synergistically interacts with focal neuronal excitotoxic damage generated by a 
striatal injection of quinolinic acid (QA) to affect the degree of striatal neuronal loss.
Results: QA injury led to comparable striatal neuronal loss and optical density of astro‑ and microgliosis in the stria‑
tum of transgenic and control mice. Respectively, no differences were identified in drug‑induced rotation behavior or 
open field behavior between the groups.
Conclusions: The failure of oligodendroglial α‑syn pathology to exacerbate striatal neuronal loss resulting from QA 
excitotoxicity contrasts with enhanced striatal neurodegeneration due to oxidative or proteolytic stress, suggesting 
that enhanced vulnerability to excitotoxicity does not occur in oligodendroglial α‑synucleinopathy like MSA.
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Background
Multiple system atrophy (MSA) is an adult-onset, pro-
gressive, neurodegenerative disorder with unknown 
etiology. MSA presents with levodopa-resistant Parkin-
sonism, cerebellar ataxia, pyramidal signs and autonomic 
failure in any combination [1]. The main pathologi-
cal hallmark of MSA is the occurrence of α-synuclein 
(α-syn)-positive glial cytoplasmic inclusions (GCIs) that 
are predominantly found in oligodendroglial cells [2]. 
MSA is thought to be a primary oligodendrogliopathy 
[3]. Furthermore, striatonigral degeneration (SND) and 
olivopontocerebellar atrophy (OPCA) are described to 
underlie the motor symptoms [4, 5]. Although the occur-
rence of GCIs is recognized as a fundamental factor in 
the pathogenesis of MSA, the association of GCIs with 
neuronal degeneration in MSA remains unclear. In addi-
tion, neuroinflammation, excitotoxicity, proteasomal dys-
function and oxidative stress are thought to be involved 
in the neurodegenerative process of MSA [6–11]. Experi-
mental models provide an important tool to study the 
disease mechanisms and test new therapeutic targets in 
MSA [12]. The development of a transgenic mouse model 
which reproduces GCI-like aggregations by overexpres-
sion of α-syn under control of the proteolipid-protein 
promoter (PLP) [13] or the myelin basic protein (MBP) 
[14] in oligodendroglial cells has been instrumental to 
address mechanisms of MSA-like neurodegeneration [12, 
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15–19]. Systemic exposure of transgenic PLP-α-syn mice 
to the mitochondrial toxin 3-nitropropionic acid (3-NP) 
resulted in dose-dependent MSA-like neurodegenera-
tion supporting the role of systemic oxidative stress in 
the pathogenesis of this disorder [12, 20]. Oligodendro-
glial α-syn overexpression in PLP-α-syn mice as well as 
MBP-α-syn mice resulted in increased 3-NP vulnerability 
associated with oxidative changes of α-syn pathology in 
oligodendrocytes that may partly mediate the enhanced 
neuronal vulnerability to systemic stress [12, 21, 22]. Sup-
porting this notion, systemic exposure to proteasome 
inhibition triggered wide-spread MSA-like neurodegen-
eration in transgenic PLP-α-syn mice but not in wild type 
controls highlighting the importance of aggravated oligo-
dendroglial α-syn pathology through systemic proteolytic 
stress for increased neuronal vulnerability [23].
Abnormally enhanced glutamatergic neurotransmis-
sion may cause excitotoxic cell damage and lead to neu-
ronal death that has been classically associated with 
Huntington’s disease [24] and amyotrophic lateral scle-
rosis [25] among others. Excitotoxic neuronal injury has 
been suggested in MSA [10] but the evidence is sparse. 
Alternatively, a large phase III randomized placebo-con-
trolled trial of riluzole, an anti-excitotoxicity drug, failed 
to modify overall severity and progression in MSA [26] 
adding to the controversy on the role of excitotoxicity in 
this disorder.
Quinolinic acid (QA) is a useful tool to address excito-
toxic pathways in models of neurodegenerative disorders. 
QA is known for its potential to selectively activate the 
N-methyl-d-aspartate (NMDA) sensitive subpopula-
tion of glutamate receptors [27]. It has been shown that 
already minimal amounts of QA can directly activate 
NMDA receptors or lead to the release of endogenous 
glutamate and thus induce significant neuronal damage 
[28, 29]. In the present work we aimed to combine ste-
reotactic striatal QA lesions with the oligodendroglial 
α-syn pathology in the transgenic PLP-α-syn MSA mouse 
model to identify whether the preceding α-syn toxicity 
may enhance excitotoxic injury and striatal neuronal loss 
and thus play a specific role in MSA pathogenesis. There-
fore, QA was stereotactically injected into the striatum of 
transgenic PLP-α-syn and control mice. The excitotoxin-
induced motor impairment and striatal neuronal loss was 
comparable in transgenic PLP-α-syn and control mice.
Methods
Animals and surgery
This animal experiment was performed in accordance 
with the ethical guidelines and with the specific permis-
sion of the Ethics Committee at the Austrian Federal 
Ministry of Science and Research (BMWF-66.011/0041-
II/3b/2011). All efforts were made to minimize animal 
suffering and to reduce the number of animals used. The 
mice were housed under 12 h light/dark-cycle with free 
access to food and water. In the present study we used 
seven-month old transgenic PLP-α-syn mice (n = 8) and 
age-, sex- and background-matched healthy control mice 
(n = 7). To assess the effects of QA all animals received 
stereotaxic injections of 90  nmol QA (Sigma-Aldrich, 
USA) into the left striatum (AP +0.7 mm, ML +2.0 mm, 
V −3.0  mm) under deep inhalation isoflurane (Abbott, 
USA) anaesthesia using 4 vol % for induction and 1.5–2 
vol % intrasurgically.
Behavioral tests
Behavioral tests were done 15  weeks post surgically to 
assess the effects of QA striatal lesion.
Open field activity
To investigate the locomotor activity of the two groups 
the flex field activity test (San Diego Instruments, 
USA) was performed as previously described [12]. 
Briefly, mice were placed in the center of the open field 
(40.5 × 40.5 × 36.5 cm) and the horizontal and vertical 
(rearing) locomotor activity was measured for 15  min. 
The tests were performed in a dark room with complete 
isolation from external noises during the test period.
Drug induced rotations
The well-established automated rotometer system (San 
Diego Instruments, USA) was applied to assess rotational 
asymmetry as described previously [30, 31]. Amphet-
amine-induced rotations were measured for 60  min 
upon intraperitoneal injection of d-amphetamine sul-
fate (5  mg/kg, dissolved in 0.9  % sterile saline, Sigma-
Aldrich, Austria). Apomorphine-induced turnings were 
quantified for 60  min upon subcutaneous apomorphine 
hydrochloride injections (0.5 mg/kg, dissolved in 0.2 mg/
mL ascorbic acid in 0.9  % sterile saline, Sigma-Aldrich, 
Austria) [32, 33]. Only total turns (360°) to the left and 
to the right were counted. Amphetamine tests were ana-
lyzed based on net ipsilateral (left–right) turns and apo-
morphine tests were analyzed based on net contralateral 
(right–left) turns [31].
Tissue processing
After the behavioral recordings were completed, animals 
were transcardially perfused under deep thiopental anes-
thesia with phosphate buffered saline (PBS) followed by 
ice-cold 4  % paraformaldehyde (PFA) (pH 7.4) (Sigma-
Aldrich, Austria). Brains were removed and post-fixed 
in 4 % PFA overnight at 4  °C and then cryoprotected in 
30 % sucrose. Subsequently, brains were slowly frozen in 
2-methylbutan and preserved at −80  °C until process-
ing. Tissue was sliced on a freezing microtome (Leica, 
Page 3 of 10Kuzdas‑Wood et al. BMC Neurosci  (2015) 16:86 
Nussloch, Germany) into 8 coronal series throughout 
striatal levels (Bregma levels from +1.78 to −2.3).
Immunohistochemistry
The following antibodies were used in this study: mouse 
anti-dopamine- and cAMP-regulated phosphoprotein 
(DARPP-32, 1:5000, BD Biosciences, USA), monoclonal 
rat anti-CD11b (1:150, Serotec, UK), mouse anti-glial 
fibrillary acidic protein (GFAP, 1:1000, Millipore, USA), 
rat polyclonal antibody to human α-syn (15G7, 1:200, 
Enzo Life Sciences, Germany) and rabbit monoclonal 
[1536Y] antibody to phosphorylated α-syn (pSyn, 1:1000, 
Abcam, UK). Secondary antibodies were biotinylated 
horse anti-mouse IgG and biotinylated goat anti-rat or 
anti-rabbit IgG (Vector Laboratories, USA). For the visu-
alization of the immunohistochemical binding sites ABC 
complex (Vector Laboratories, USA) and 3,3’-diamin-
obenzidine were used. Sections were mounted on slides 
and coverslipped with Entellan.
Image analysis
All quantification analyses were done on a Nikon 
Eclipse E800 microscope equipped with Nikon cam-
era DXM1200 and Stereo Investigator Software (Micro 
Bright Field Europe, Germany) by an experimenter who 
was blinded to the genotype of the animals. The optical 
fractionator method was used to estimate the number 
of DARPP-32-immunopositive GABAergic medium-
sized spiny neurons in the lesioned and the contralateral 
non-lesioned striatum. The number of GCI-like α-syn 
inclusion per mm2 in 15G7 and pSyn immunostaining 
was determined in the lesioned and non-lesioned stria-
tum [23, 34]. To analyze astrogliosis (GFAP) and micro-
glial activation (CD11b), the optical density (OD) of 
the lesioned and non-lesioned striatum was defined at 
standard camera settings as previously described [35]. 
GCI density was quantified In any case the area of the 
striatum was delineated at the respective bregma level 
according to the Mouse Brain Atlas [36].
Statistical analysis
After completion of the blinded image analysis the 
results were de-coded and appointed to the respec-
tive experimental group. All statistical analyses were 
performed using Graph-Pad Prism 5 (Graphpad Soft-
ware, San Diego, CA, USA) and the results were pre-
sented as the mean ± SEM. Five control mice and eight 
PLP-α-syn mice with successful intrastriatal needle 
tract placement and identification were included in 
the statistical analysis. Unpaired t test was used for 
the comparison of the behavioral performance of the 
two groups. Two-way ANOVA was used with variables 
genotype (control vs PLP-α-syn) and side (lesioned vs 
non-lesioned). A P value <0.05 was considered statisti-
cally significant.
Results
Oligodendroglial α‑syn accumulation does not magnify the 
deterioration of motor performance induced by unilateral 
QA striatal lesions
Drug-induced rotation behavior resulting from a QA 
lesion in the left striatum revealed no significant differ-
ences between PLP-α-syn and control mice. The number 
of amphetamine-induced net ipsilateral rotations over 
a period of 60  min was comparable in PLP-α-syn and 
control mice (Fig.  1a). As previously reported [31] and 
expected negligible rotation behavior was induced by 
apomorphine after a unilateral QA striatal lesion, with 
no significant difference between PLP-α-syn and control 
mice (Fig.  1b). General locomotor activity in the verti-
cal (rearing) and horizontal plane in an open field arena 
showed no differences between QA lesioned PLP-α-syn 
mice and control mice (p > 0.05) (Fig. 1c, d).
Oligodendroglial α‑syn accumulation does not enhance 
striatal excitotoxic lesions by focal QA injection
The loss of GABAergic medium-sized spiny neurons 
induced by 90 nmol QA injections into the left striatum 
was comparable in PLP-α-syn and control mice (stri-
atal neuronal loss of 247464 ± 54192.97 in QA-lesioned 
control animals compared to 252596 ± 48682.83 in QA-
lesioned transgenic PLP-α-syn MSA animals, Fig. 2).
Excitotoxic insult by QA classically leads to neuroin-
flammatory response with activation of astroglia and 
microglia in the lesioned striatum [37, 38]. To assess 
the glial responses as a measure of the QA lesion extent 
we measured the optical density of GFAP and CD11b 
immunohistochemical stainings in the lesioned and 
non-lesioned striatum, respectively. Astroglial activa-
tion was induced by QA in both PLP-α-syn (ODGFAP 
0.172 ± 0.012) and control mice (ODGFAP 0.194 ± 0.01) 
regarding the lesioned striatum with no significant differ-
ences in the OD of GFAP immunoreactivity in the stria-
tum between the groups. Regarding the non-lesioned 
striatum no significant differences between the groups 
were detected (control mice ODGFAP 0.109 ± 0.004, PLP-
α-syn ODGFAP 0.102 ± 0.005) (Fig. 3).
Microglial activation tended to be higher in the 
non-lesioned striatum of PLP-α-syn mice (ODCD11b 
0.1  ±  0.014) as compared to control animals (ODCD11b 
0.074  ±  0.01), however this difference as measured by 
the OD of CD11b immunoreactivity in the striatum did 
not reach significance (Fig.  4). The microglial activa-
tion increased significantly in the QA lesioned striatum 
of both control (ODCD11b 0.166 ± 0.018) and PLP-α-syn 
mice (ODCD11b 0.191  ±  0.022). Although there was a 
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slight trend towards greater microglial activation in the 
lesioned striatum of PLP-α-syn as compared to control 
mice, the difference did not reach statistical significance 
in terms of ODCD11b.
Due to the overexpression of human α-syn under the 
PLP promotor in the PLP-α-syn mice accumulation of 
α-syn is present in oligodendrocytes (Fig. 5). GCI density 
was analyzed in non-lesioned (Fig.  5a, b) and lesioned 
(Fig. 5c, d) striatum of PLP-α-syn mice revealing no sta-
tistical significant difference regarding the number of 
GCIs per mm2 (Fig. 5e, f ).
Discussion
Given that not much is known about the etiopathogene-
sis of MSA and that there is lack of adequate treatment to 
stop the progression of the disease [1], the understanding 
of MSA pathophysiology is of tremendous importance. 
Different approaches have been used in the past aiming 
to generate MSA mouse models that replicate not only 
the pathology but also provide insights into the patho-
genic mechanisms relevant to the disease [12, 21, 23]. 
Several studies suggested a role of excitotoxicity in neu-
rodegenerative diseases including MSA [10, 24, 25, 39]. 
However, it is currently unclear, if pathological aggrega-
tion of α-syn in oligodendrocytes may enhance the sus-
ceptibility to excitotoxic stress in MSA as it has been 
shown to be the case with oxidative stress and protea-
some dysfunction [12, 23].
The current study, for the first time, characterized the 
effect of unilateral stereotactic injection of the excito-
toxin QA into the striatum of the transgenic PLP-α-syn 
mouse model of MSA to assess whether excitotoxic insult 
may be aggravated by oligodendroglial α-syn pathology. 
The excitotoxic lesion of the striatum of transgenic PLP-
α-syn mice was comparable to the one induced by the 
same treatment paradigm in control mice as measured by 
functional and neuropathological readouts. Therefore, it 
can be concluded that the occurrence of α-syn aggregates 
in oligodendroglial cells in the transgenic PLP-α-syn 
mouse does not potentiate the effect of QA excitotoxic-
ity on medium-sized spiny striatal neurons compared to 
control mice at 7 months of age.
Although a tendency toward lower number of GABAe-
rgic medium-sized spiny neurons was seen in the non-
lesioned striatum of PLP-α-syn mice versus controls, the 
difference was not significant. The additional excitotoxic 
Fig. 1 Behavioral analysis 15 weeks after unilateral QA lesion in the striatum in PLP‑α‑syn and control mice. Amphetamine‑ and apomorphine‑
induced rotations were presented as net ipsilateral or contralateral turns in a test period of 60 min (a, b). Open field activity—horizontal and vertical 
(rearing) were automatically detected over a period of 15 min (c, d). Data are mean ± SEM
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Fig. 2 DARPP‑32 neuronal loss in the left striatum after 90 nmol QA injection in PLP‑α‑syn and control mice. Overview of the unilaterally QA 
lesioned striatum in control (a) and PLP‑α‑syn mice (b) is demonstrated in representative sections at low magnification. In the non‑lesioned side 
immunopositive neurons were easily detectable (arrows) at high magnification both in control (c) and PLP‑α‑syn mice (d). There was loss of DARPP‑
32 neurons, identifying only few preserved ones (arrow) or some degenerating cell profiles (arrowheads) on the lesioned side in controls (e) and 
PLP‑α‑syn mice (f). Statistical analysis with two‑way ANOVA showed comparable neurodegeneration in control and PLP‑α‑syn mice (g). Data are 
presented as mean ± SEM. ***p < 0.001. L lesioned side, NL non‑lesioned side
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insult induced by intrastriatal injection of 90  nmol QA 
did not reveal differences in the vulnerability of striatal 
neurons to NMDA mediated toxicity in the presence 
or absence of oligodendroglial α-syn pathology. In both 
cases (transgenic and non-transgenic mice) striatal neu-
ronal loss was about 70 %. It is interesting to note that in 
contrast to QA, another classically selective striatal neu-
rotoxin with a different mode of action, i.e. 3-NP systemi-
cally applied—a mitochondrial complex II inhibitor—, 
shows increased striatal toxicity in PLP-α-syn mice and 
furthermore induces neuronal loss in regions (cerebel-
lum, pons, inferior olives) that are classically not affected 
by 3-NP toxicity in wild type mice [12]. These differences 
in the vulnerability to QA and 3-NP of PLP-α-syn mice 
may reflect the divergent actions of the two neurotoxins. 
It is possible that the wide-spread mitochondrial dys-
function linked to systemically applied 3-NP treatment 
may influence the oligodendroglial support of neurons, 
Fig. 3 GFAP immunohistochemistry to study astroglial activation due to QA striatal lesion. In the non‑lesioned side GFAP‑immunopositive astroglial 
cells were few in number, not activated and easily detectable at high magnification both in control (a) and PLP‑α‑syn mice (b). There was intense 
astroglia activation following QA injection on the lesioned side in both controls (c) and PLP‑α‑syn mice (d). Statistical analysis with two‑way 
ANOVA showed comparable astroglial activation in control and PLP‑α‑syn mice as measured by GFAP optical density (e). Data are presented as 
mean ± SEM. ***p < 0.001. OD optical density
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which leads to neuronal loss in additional brain regions. 
In contrast, QA appears to trigger primary striatal neu-
ronal death through NMDA mediated excitotoxicity 
without significant contribution of the oligodendroglial 
α-synucleinopathy in this context. This notion is sup-
ported by the finding that QA lesion did not significantly 
affect the density of GCIs in the striatum. We cannot 
exclude, however, that the different mode of applica-
tion of the toxins (sub-chronic systemic for 3-NP versus 
acute local intracerebral for QA) may also contribute to 
the observed responses. Furthermore, we cannot exclude 
that intracerebral QA injections of 90 nmol into the stria-
tum might have been too severe and therefore masked a 
further potentiation of the lesion size by the oligodendro-
glial α-syn pathology in the PLP-α-syn mouse model. In 
addition, at this stage it cannot be excluded that the age 
of the transgenic animals might interfere with the vulner-
ability to QA.
The similar unilateral striatal lesion size in PLP-α-syn 
and control mice was consistent with the behavioral 
Fig. 4 CD11b immunohistochemistry to study microglial activation after QA striatal lesion. In the non‑lesioned side CD11b‑immunopositive 
cells were easily detectable at high magnification both in control (a) and PLP‑α‑syn mice (b). There was intense microglia activation following QA 
injection on the lesioned side in both controls (c) and PLP‑α‑syn mice (d). Statistical analysis with two‑way ANOVA showed comparable intensity of 
microglial activation in control and PLP‑α‑syn mice as measured by CD11b optical density (e). Data are presented as mean ± SEM. ***p < 0.001. OD 
optical density
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readouts. Similar to previous reports [31] the QA uni-
lateral striatal lesion in both control and PLP-α-syn mice 
induced comparable modest ipsilateral turning under 
amphetamine and no net rotational bias under apomor-
phine treatment. Classically doses lower than 0.5  mg/
kg b.w. apomorphine can efficiently induce contralat-
eral rotations in the unilateral 6-OHDA mouse model, 
where hypersensitivity of the dopamine receptors in the 
unilateral striatum is present [40]. However, in the QA 
lesion model apomorphine is expected to induce ipsilat-
eral rotations due to the activation of striatal dopamine 
receptors in the non-lesioned side. We cannot exclude 
that higher drug doses might have been able to trigger 
apomorphine-induced rotations in the current QA lesion 
paradigm. Although the rotational data were normally 
distributed in the present study, we observed high intra-
group variability of the rotation behavior that may reflect 
some variability in the precise location of the neostri-
atal lesion as suggested in earlier studies [31]. Previ-
ous reports in the QA model of HD [41] have suggested 
effects of the unilateral excitotoxic lesion on the rearing 
open field behavior. The current results demonstrate that 
Fig. 5 GCI‑like pathology in PLP‑α‑syn mice. 15G7 and pSyn immunohistochemistry was applied to visualize GCIs in the non‑lesioned (a, b) and 
lesioned (c, d) striatum. Statistical analysis using student’s t test showed comparable density of α‑syn‑positive GCI‑like inclusions in the non‑lesioned 
and lesioned striatum of PLP‑α‑syn mice with both 15G7 antibody (e) and pSyn antibody (f). Data are presented as mean ± SEM
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α-syn oligodendroglial pathology does not have a cumu-
lative effect with the QA insult in the transgenic MSA 
model to affect either rearing or horizontal activity in an 
open field arena.
An important feature of the excitotoxic lesions induced 
by QA is the neuroinflammatory response usually esti-
mated by astroglial and microglial activation [37, 38]. We 
observed a similar degree of astroglial activation as meas-
ured by GFAP immunoreactivity optical density in PLP-
α-syn and control mice due to the unilateral QA striatal 
lesion. Consistent with our previous work microglial 
activation assessed by optical density of CD11b immu-
noreactivity tended to be increased in the non-lesioned 
striatum of transgenic versus control mice but QA lesion 
was not associated with a significant difference in the 
microglial response between PLP-α-syn and control mice 
supporting the notion of lack of a significant cumulative 
effect between oligodendroglial α-syn accumulation and 
excitotoxic insults.
In the PLP-α-syn mouse model α-syn is expressed under 
the oligodendroglial promoter PLP and mice feature GCI-
like inclusion pathology as shown previously [12, 42]. Fur-
thermore, pathological α-syn accumulation is already present 
in the PLP-α-syn mouse model at the age of 7  months as 
shown here. In the current study, we did not observe changes 
in the accumulation of α-syn in the PLP-α-syn model upon 
striatal stereotaxic injections of QA suggesting that QA does 
not influence α-syn aggregation pathology in oligodendro-
glial cells. This finding further implies the absence of sig-
nificant cumulative effects between an excitotoxic insult and 
oligodendroglial α-syn accumulation.
Conclusions
In conclusion, here we report for the first time the impact 
of a striatal excitotoxic insult in the PLP-α-syn mouse 
model of MSA. Taken together, the present data suggest 
that QA induces severe striatal neurodegeneration with-
out any difference between transgenic and control mice. 
Therefore, the current results do not support a cumula-
tive effect of oligodendroglial α-syn accumulation and 
excitotoxicity to induce MSA-like neurodegeneration in 
contrast to oxidative or proteolytic stress [12, 23].
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